Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat
| Status: | Completed |
|---|---|
| Conditions: | Hematology |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 6/16/2018 |
| Start Date: | April 2015 |
| End Date: | April 2018 |
Cognitive Function and Patient-Reported Psychological and Functional/Quality of Life Outcomes Investigation in Patients Taking Vorinostat for Graft-versus-Host Disease Prophylaxis
Psychological well-being and cognitive function will be measured in patients enrolled on the
primary study, NCT01790568, a phase 2 trial of vorinostat plus tacrolimus and methotrexate to
prevent graft versus host disease following unrelated donor hematopoietic stem cell
transplantation. Validated questionnaires will be administered to assess patients' level of
depression, anxiety, quality of life, perceived cognitive functioning, and sleep quality.
Cognitive testing will include reliable and valid measures of processing speed, attention,
executive function, episodic memory, and visual learning and memory. The purpose of this
study is to determine whether these measures are feasible to administer in patients before
and at early time points after bone marrow transplantation .
primary study, NCT01790568, a phase 2 trial of vorinostat plus tacrolimus and methotrexate to
prevent graft versus host disease following unrelated donor hematopoietic stem cell
transplantation. Validated questionnaires will be administered to assess patients' level of
depression, anxiety, quality of life, perceived cognitive functioning, and sleep quality.
Cognitive testing will include reliable and valid measures of processing speed, attention,
executive function, episodic memory, and visual learning and memory. The purpose of this
study is to determine whether these measures are feasible to administer in patients before
and at early time points after bone marrow transplantation .
Inclusion Criteria:
- Patients must be enrolled on the parent study (NCT01790568; A phase 2 clinical trial
of vorinostat plus tacrolimus and methotrexate to prevent graft versus host disease
following unrelated donor hematopoietic stem cell transplantation)
- Must speak, read and understand English
Exclusion Criteria:
- Documented evidence of cognitive impairment prior to enrollment on this study
(diagnosis of dementia, mild cognitive impairment, or other neurological illnesses
that impact cognition).
We found this trial at
1
site
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
Principal Investigator: Sung Choi, MD, MS
Phone: 734-615-5707
University of Michigan Health System The University of Michigan is home to one of the...
Click here to add this to my saved trials
